Biologics patent expiry to positively impact US pharma, says report
New research has suggested that the expiration of biologics patents will be the factor that positively impacts US pharma the most this year.
List view / Grid view
New research has suggested that the expiration of biologics patents will be the factor that positively impacts US pharma the most this year.
Following 250 US drug price increases in 2020 already, this article explores why costs are rising, what changes could ensure brand reputations remain intact and what manufacturers can do to ensure they get their share.
A trastuzumab biosimilar has been pre-qualified by WHO, marking its first, to improve access to the breast cancer treatment.
The EC has released a report that has found generics and biosimilars decrease wasteful spending and maintain health quality in the EU.
Remsima SC™ is the world’s first subcutaneous formulation of infliximab and has been approved in the EU for the treatment of people with rheumatoid arthritis.
The FDA has approved Sandoz's biosimilar Ziextenzo and the company now intends to launch it in the US as soon as possible this year.
A new biosimilar drug to treat osteoporosis is now available across Europe after the patent for its reference product expired.
The US District Court has decided in favour of Amgen’s Enbrel, ruling over Sandoz’s Erelzi in a patent conflict.
2019 has seen a marked increase of antibody biosimilar product approvals in the first half of the year, according to a report.
The FDA has approved RUXIENCE (rituximab-pvvr), a biosimilar to Rituxan® (rituximab), for treatment of non-Hogkin’s lymphoma and other conditions.
Former FDA Commissioner, Scott Gottlieb, who stepped down from the administration in April, has joined Pfizer’s board of directors.
A study has predicted that the global biopharmaceutical contract manufacturing market will grow by 10.6 percent from 2017 to 2027.
The global biobetters market is set to increase due to demand for higher efficacy and safer drugs.
The EMA has accepted Prestige BioPharma’s marketing application for its trastuzumab biosimilar.
British Columbia has said it will switch as many as 20,400 patients from three branded biologic drugs to cheap biosimilars.